改良Morrow手术治疗21例肥厚梗阻型心肌病临床分析

目的 评价改良Morrow手术治疗肥厚梗阻型心肌病(HOCM)的临床疗效。方法 回顾性分析我院2013年8月~2014年7月应用改良Morrow手术治疗的21例HOCM患者临床资料。所有患者均为药物治疗效果不佳,其中男9例,女12例,年龄22~64(45.3±11.9)岁。所有患者均行改良Morrow手术,包括扩大的肥厚心肌切除和游离肥厚的二尖瓣前乳头肌,其中2例患者同时行二尖瓣前叶折叠。对比研究所有患者手术前后左室流出道梗阻、二尖瓣功能和临床症状改变,评价改良Morrow手术疗效。结果 全组21例患者无死亡。术中切除心肌质量8.5~22.8（14.9±3.8） g。术中Ⅲ度房室传导阻滞1例,安置心脏永久起搏器。术后患者左室流出道压差显著降低〔术前（101±41）mmHg vs.术后（10±8）mmHg〕（P<0.01）,左室流出道最狭窄内径显著增宽〔术前（5.0±2.1）mm vs.术后（16.6±3.6）mm〕（P<0.01）,左房内径明显减小〔术前（47±5）mm vs.术后（42±5）mm〕（P<0.01）,二尖瓣返流量显著减少〔术前（5.9±3.7）ml vs.术后（1.8±1.5）ml〕（P<0.01）。18例术前SAM征阳性患者术后SAM征均消失,19例患者胸闷、气短症状消失,90%患者心功能为Ⅰ级。结论 改良Morrow手术能够有效解除左室流出道梗阻,改善二尖瓣功能,是治疗药物无效HOCM的有效手段。     

儿童梗阻性肥厚型心肌病外科手术疗效评估的初步研究

摘要 目的 探讨儿童梗阻性肥厚型心肌病（hypertrophic obstructive cardiomyopathy,HOCM）患者行改良扩大Morrow手术（室间隔旋切术）治疗HOCM的临床疗效、安全性及并发症。 方法 回顾性分析2015年8月至2018年12月在西京医院肥厚型心肌病诊治中心就诊的8例行改良扩大Morrow术的HOCM儿童（年龄＜18岁）的临床资料、基因学资料和术后随访结果,总结外科手术后早中期临床疗效、安全性及并发症情况。 结果 全组手术顺利,无围手术期死亡;所有患儿临床症状明显改善,纽约心功能分级Ⅰ或Ⅱ级。随访静息左室流出道压力阶差（left ventricular outflow tract gradient,LVOTG）较术前明显下降(35.5±21.3mmHg vs 80.5±27.9mmHg,P＜0.01,1mmHg=0.133kPa）,术后3例（37.5%）出现完全性左束支传导阻滞,1例并发三度房室传导阻滞并行永久性心脏起搏器植入术。其中3例患儿术后8月-1年复发,左室流出道梗阻（left ventricular outflow tract obstruction, LVOTO）复发率37.5%。基因结果示：基因检出率可达75%,其中5例患儿携带肌小节蛋白突变,占62.5%;1例携带RAF1基因突变,占12.5%;1例无明确基因突变。患者随访26.5±14.7月,8例患者均存活,无心源性猝死发生。 结论 改良扩大Morrow术（室间隔旋切术）是治疗儿童HOCM的有效方式,可有效改善患儿症状,缓解左室流出道梗阻;术后易并发左束支传导阻滞,有复发可能,基因检测有助于HCM患儿的精准诊治和临床随访。     

改良扩大Morrow手术治疗儿童肥厚型梗阻性心肌病的临床研究

目的:分析改良扩大Morrow手术(室间隔心肌切除术)治疗儿童肥厚型梗阻性心肌病(HOCM)的近期和远期疗效。方法:回顾性分析中国医学科学院阜外医院对2010-01至2017-07实施改良扩大Morrow手术的50例HOCM患儿(年龄≤14岁)住院结局、围术期以及远期超声心动图(UCG)变化。结果:47例患儿术后症状明显改善或消失,1例术后因停机困难行体外膜肺氧合(ECMO)辅助120 h脱机后出院,2例术后死于肺部感染;3例发生三度房室阻滞。与术前相比,患儿室间隔厚度(IVST)显著减小[(14.3±6.7)mm vs(21.2±9.7)mm,P0.001],左心室流出道压力阶差(LVOTG)明显降低[(19.6±17.3)mmHg vs(74.8±25.0)mmHg,P0.01,1 mmHg=0.133 kPa]。仅4例(8.5%)术后仍存在二尖瓣前向运动(SAM)。45例存活患儿平均随访(27.7±14.0)月,纽约心脏协会(NYHA)心功能分级均为Ⅰ级或Ⅱ级,UCG示LVOTG[(15.5±12.5)mmHg vs(74.8±25.0)mmHg]和IVST[(14.3±7.9)mm vs(21.2±9.7)mm]仍较低(P均0.01)。结论:改良扩大Morrow手术可明显改善HOCM患儿的症状及心功能,远期结果满意。     

经皮经冠状动脉室间隔化学消融术治疗梗阻性肥厚型心肌病的近期疗效观察

目的评价经皮经冠状动脉室间隔化学消融术（PTSMA）治疗梗阻性肥厚型心肌病（HOCM）的近期疗效。方法自1998年8月～1999年11月收治HOCM34例,入选行PTSMA26例。利用Sigwart法行PTSMA,注入96%～99%无水酒精消融间隔支前后记录左室流出道压力阶差变化、心电图变化。在消融前及术后2周通过超声心动图测量室间隔（IVS）厚度及左室流出道宽度。结果术前平均静息左室流出道压力阶差为（72.8±24.6）mmHg（1mmHg=0.133kPa）,术中球囊加压后为（30.6±18.5）mmHg,术后为（24.3±17.6）mmHg,差异有显著性（P<0.001）。术前室间隔平均厚度为（23.00±6.03）mm,术后2周为（20.55±5.38）mm。术前左室流出道宽度为（6.54±2.36）mm,术后2周为（11.36±3.37）mm（P<0.01）。术前心功能（NYHA分级）为3.4±0.6,术后2周为1.6±0.8。术后CPK与CPK-Mb峰值分别为（1050±514）U/L与（131±78）U/L。术中及术后可见短阵室速、结性逸搏心律、三度房室传导阻滞及束支传导阻滞。1例发生永久性三度房室传导阻滞,安装永久性双腔起搏器。出现下壁及前壁心肌梗死心电图表现者各1例。结论PTSMA能显著降低左室流出道压力阶差,治疗HOCM的近期疗效可靠,但尚需进一步完善方法,以减少严重并发症发生,并需继续随访其中、远期疗效。     

改良扩大Morrow手术治疗青少年肥厚型梗阻性心肌病患者的早期疗效分析

目的:评价改良扩大Morrow手术(室间隔心肌切除术)治疗青少年肥厚型梗阻性心肌病(HOCM)的早期手术疗效。方法:回顾性分析我院2011年至2015年改良扩大Morrow手术治疗29例青少年(≤21岁)HOCM患者的临床资料,评价早期手术疗效。术前、术后超声心动图检查比较左心房前后径、左心室舒张末期内径、左心室射血分数、室间隔厚度、左心室流出道峰值压差、二尖瓣收缩期前向运动征和二尖瓣反流分级变化,同时抽血检测术前、术后血浆N末端B型利钠肽原水平变化,采用纽约心脏协会心功能分级评估心功能。结果:本组患者中,接受单纯改良扩大Morrow手术者17例(58.6%),同时行冠状动脉旁路移植术者8例(27.6%)。与术前比较,改良扩大Morrow手术后患者的室间隔厚度显著减小[(24.6±6.8)mm vs(16.9±7.1)mm,P0.01],左心室流出道峰值压差明显降低[(68.8±15.7)mm Hg(1 mm Hg=0.133 k Pa)vs(10.7±4.2)mm Hg,P0.01],二尖瓣反流明显减轻[(1.7±1.3)级vs(0.2±0.4)级,P0.01],纽约心脏协会心功能分级显著改善[(3.4±0.8)级vs(1.4±0.5)级,P0.01],血浆N末端B型利钠肽原水平显著下降[(1957.6±392.5)ng/ml vs(458.7±161.0)ng/ml,P0.01]。无围手术期死亡。术后第12、24、36个月患者的生存率分别为100.0%、86.7%和86.7%。结论:改良扩大Morrow手术是治疗青少年HOCM安全、有效的手段,术中充分暴露是保证手术效果的重要措施。     

不同术式治疗肥厚型梗阻性心肌病效果的研究

目的:本研究是比较肥厚型梗阻性心肌病(HOCM)患者接受经典Morrow术和改良Morrow术的手术效果。方法:从2008年12月到2016年12月,我院对有症状的HOCM患者共236例进行了手术治疗。其中86例接受经典术,150例接受改良术。记录患者围手术期的血流动力学资料及随访资料。结果:两种术式术前和术后左心室室间隔厚度[经典M术(22.1±11.9)vs.(17.1±4.0)mm;改良术(22.3±4.4)vs.(16.1±3.5)mm,P0.01],左心室流出道压差[(经典术[73.9(55.8,100.0)vs.10.2(7.0,14.4) mmHg,1 mmHg=0.133 kPa],改良术[73.9(55.8,100.0)vs. 10.2(7.0,14.4)mmHg,P0.01]。患者接受两种手术方式后室间厚度、左心室流出道压差明显降低,但改良组患者术后左心室流出道流速和压差比经典组下降更明显。结论:经典术和改良术均能降低HOCM患者左心室流出道梗阻,但改良术对于左心室流出道梗阻的缓解更好。     

经胸超声心动图术中监测经皮腔内室间隔心肌消融术治疗肥厚性梗阻型心肌病

【】 目的 探讨经胸超声心动图术中监测在经皮腔内室间隔心肌消融术(percutaneous transluminal septal myocardial ablation,PTSMA)治疗有症状的肥厚性梗阻型心肌病(hypertrophic obstructive cardiomyopathy, HOCM)中的临床应用价值。方法 2011年1月至2015年1月在经胸超声心动图监测下对39例HOCM患者行心肌造影(myocardial contrast echocardio-graphy, MCE),超声定位及矫正与肥厚梗阻靶区域相匹配的拟消融靶血管,测量心脏PTSMA术前及术后各参数值,并进行比较。结果 2例(5%)HOCM患者未找到匹配的间隔支血管,37例(95%)找到与梗阻区域相匹配的靶血管支,成功行PTSMA。术前舒张期室间隔厚度2.12±0.32mm,术后2.05±0.31mm;术前收缩期左室流出道内径1.19±0.39 mm,术后1.41±0.38mm;术前超声测量左室流出道压力阶差70.01±40.30mmHg,术后29.00±16.99mmHg;差异均有统计学意义(P<0.001)。LVOTPG超声及导管测量术前及术后均有较好相关性,术前r=0.505,术后r=0.501,P<0.01。术前37例患者均伴不同程度的SAM运动,术后SAM运动均消失。二尖瓣反流程度术前与术后比较差异有统计学意义(P<0.001)。术后未发现室间隔穿孔,心包填塞,室间隔及左室壁节段性运动异常等并发症。结论 经胸超声心动图的术中监测对经皮腔内室间隔心肌消融术靶血管的选择具有重大作用,并可实时动态观察消融术中心脏各参数变化,使患者获得治疗上的最大收益又能降低医疗风险,具有重要的临床价值。     

经皮室间隔心肌消融术治疗老年肥厚型梗阻性心肌病的临床分析

目的　探讨经皮室间隔心肌消融术治疗老年肥厚型梗阻性心肌病 (HOCM)的可行性 ,安全性和近期效果。方法　对 6 0岁以上的 6例老年HOCM患者施行心肌声学造影指导下的经皮室间隔心肌消融术治疗。结果　 6例患者的经皮室间隔心肌消融术均获成功 ,未出现严重的心脏并发症 ,术后即刻应用心导管测左室流出道压差由术前(10 4.33± 19.6 1)mmHg降至 (35± 2 5 .88)mmHg(P <0 .0 0 1)。术后对 6例患者进行了 1～ 18个月的随访 ,经超声心动图测左室流出道压差由术前 (91.83± 2 7.17)mmHg降至 (36 .0 8± 33.6 3)mmHg(P <0 .0 5 ) ,室间隔厚度由术前(2 1.83± 2 .79)mm降至 (16 .0 2± 3.86 )mm (P <0 .0 5 )。术后心功能由术前的 3.4± 0 .5级改善为 1.1± 0 .3级 (P <0 .0 0 1)。结论　经皮室间隔心肌消融术治疗老年HOCM患者的即刻和近期效果良好 ,并发症少 ,安全性高。     

经典Morrow手术治疗肥厚型梗阻性心肌病30例疗效分析

目的:观察经典Morrow手术治疗肥厚型梗阻性心肌病(HOCM)患者的临床效果。方法:纳入2011年12月—2018年1月在天津市胸科医院行经典Morrow手术治疗的30例肥厚型梗阻性心肌病患者,平均年龄(56.5±8.6)岁。比较手术前、术后早期和随访期经胸超声心动图结果,评价手术效果。术后平均随访(23±9)个月。结果:全组患者左室流出道压差(LVOTPG)从术前(91.39±38.38)mmHg下降至(15.48±14.12)mmHg(P<0.001),二尖瓣反流明显改善(P<0.001)。术后3例患者因三度房室传导阻滞安装永久起搏器,无室间隔穿孔、瓣膜损伤等严重并发症的发生。18例接受二尖瓣置换术的患者LVOTPG下降至(10.30±8.41)mmHg(P<0.001),流出道梗阻改善更为满意,无不良事件发生。1例患者术后早期死于脑卒中,3例患者失访。随访26例患者,LVOTPG降至(6.41±7.25)mmHg,较术前明显改善。结论:经典Morrow手术可有效解除左室流出道梗阻,近中期效果满意。     

改良扩大Morrow手术治疗肥厚型梗阻性心肌病的近中期随访疗效

目的:观察改良Morrow手术治疗肥厚型梗阻性心肌病(HOCM)的近中期随访疗效。方法:选取我院2014年1月—2020年12月采用改良Morrow手术治疗的HOCM病人25例。所有病人术前均经超声心动图和心脏磁共振成像确诊为HOCM,行冠状动脉CT或冠状动脉造影,评估冠状动脉情况。所有病人均有二尖瓣前叶前向运动(收缩期前向运动征阳性)。所有病人均在全身麻醉、中度低温体外循环下经主动脉切口行改良Morrow手术,术中经食道超声评估手术效果,术后定期随诊。结果:25例病人住院期间无死亡,其中1例病人术后出现完全性房室传导阻滞,行永久起搏器置入,所有病人均治愈出院。结论:改良Morrow手术是治疗HOCM的有效方法,对药物治疗无效和乙醇消融术后再次复发的病人有效,可彻底解除左心室流出道梗阻,近中期疗效良好。     

肥厚型梗阻性心肌病的外科治疗及围术期治疗策略

目的 总结肥厚型梗阻性心肌病（Hypertrophicobstructivecardiomyopathy,HOCM）的外科治疗效果,探讨围术期治疗策略。方法 回顾性分析2012年6月至2013年10月我院由单一术扦实施外科手术治疗的HOCM忠并75例,刃性47例（47／75,63％）,女性28例（28／75,37%）．年龄10—66（42．92±15．07）岁,术前左室流出道峰值压差（LVOTGP）为50—270（86．98±42．69）mmHg（1mmHg=0．133kPa）、令=部患行均接受室间隔心肌切除术（改良扩大Morrow术）．同期行冠状动脉旁路移植术6例,室壁确切除术1例,二尖瓣置换术4．二尖瓣成形术9,主动脉瓣置换术2,三尖瓣成形术3,先心病2例．围术期常规行心脏超声心动图、心电图及胸部X线片检查,评价超声心动图检查指标、二尖瓣的结构和功能改变。结果 全组无围术期或远期死亡。全组体外循环时间66—258（J33．00±39．83）分钟,升主动脉阻断时间45—157（84．71±25．85）分钟,机械通气时间8-396（2447±44．78）小时,术后住ICU时间1-27（299±3．23）天,术后住院时间6—35（10．20±5．31）天,术后胸腔积液12例,二次插管1例,气管切外1例,床旁血液滤过治疗1例,主动脉内球囊反搏1例,无气胸、无二次开胸探查及二次手术.术后片心房内径（37.31±4．34mm vs43．50±5．89mm,P=O．000）,左室流出道峰值压差（12．31±7.00mmHg vs 86．98±42．69mmHg,P=0．000）,室间隔厚度（15．41±5．00mmvs22．34±6．20mm．P=O．000）与术前比较均减小或降低。二尖瓣关闭好或仅有轻度反流,二尖瓣前向运动（SAM征）基本消失。术后发生的主要心律失常包括完全性左束支传导阻滞、室内传导阻滞、完全性房室传导阻滞和心房颤动等。远期随访患者症状消失或仅有轻度症状,生活质量明显改善,心动能NYHA分级级别较术前降低I—II级,无远期死亡、并发症或再次手术。结论外科室间隔心肌切除术治疗肥厚型梗阻性心肌病具有良好的手术效果,能够安全有效地解除左室流出道的梗阻,消除二尖瓣SAM征,改善临床症状。术后并发症主要为心律失常表现为传导束传导异常和心房颤动．具有较好的近远期生存率。     

Echocardiographic evaluation of Carpentier mitral valvuloplasty

Carpentier's technique for reconstructive mitral valve surgery is an alternative to mitral valve replacement in patients with mitral regurgitation. The procedure involves reconstruction of the mitral valve and insertion of a ring into the mitral anulus. To study the results of this operation, pre- and postoperative M-mode, two-dimensional (2DE), and Doppler echocardiography were performed on 13 patients with severe, symptomatic mitral regurgitation, who underwent reconstructive mitral surgery. A significant clinical improvement was noted in all patients. This correlated with the hemodynamic and angiographic improvement in six of the patients who underwent postoperative cardiac catheterization. Postoperative echocardiography showed that the mitral valve E-F slope decreased from 129 ± 30 mm/sec preoperatively to 53 ± 13 mm/sec postoperatively (p < 0.001). The mitral valve excursion decreased from 28 ± 6 mm preoperatively to 19 ± 2 mm postoperatively. The left ventricular minor axis shortening decreased from 32 ± 9% to 28 ± 6%. In seven patients the mitral valve area decreased from 4.5 ± 0.9 cm² to 2.8 ± 0.5 cm² (p < 0.005). In each patient a new echocardiographic finding was observed: two parallel dense linear echoes from the prosthetic ring were noted on M-mode echocardiogrphy near the base of the mitral valve. 2DE visualized the entire ring. Doppler echocardiography suggested moderate or severe mitral regurgitation in eight of eight patients studied preoperatively. Postoperatively 10 of 11 patients had no Doppler echocardiography finding of mitral regurgitation.     

70岁以上患者同期行冠状动脉旁路移植术与心脏瓣膜手术的临床分析

目的总结70岁以上患者同期冠状动脉旁路移植术(CABG)与心脏瓣膜手术的经验。方法选择70岁以上患者同期实施冠状动脉旁路移植术与心脏瓣膜手术患者22例。主动脉瓣置换8例,二尖瓣置换3例,二尖瓣和主动脉瓣双瓣置换2例,二尖瓣成形5例,二尖瓣加三尖瓣成形2例,主动脉瓣置换加二尖瓣成形1例,二尖瓣置换三尖瓣整形1例。共旁路移植67支,平均1～5(3.1±1.7)支。结果本组围手术期无死亡。重症监护室滞留时间59～163(91.6±35.9)h,机械通气时间12～96(43.8±26.1)h,术后住院时间15～44(21.3±9.2)d。左心室舒张末内径较术前明显降低[(50.5±7.7)mmvs(56.5±10.2)mm,P<0.01)],LVEF较术前明显升高[(52.6±10.6)%vs(47.9±10.2)%,P<0.05]。术后随访6个月～1年,死亡2例。结论老年患者同期施行CABG与心脏瓣膜手术效果满意。加强围手术期管理、恰当处理瓣膜病变、心肌充分再血管化、良好心肌保护和缩短心肌缺血时间是手术成功的关键因素。     

经皮室间隔化学消融治疗肥厚型梗阻性心肌病疗效观察

<正>肥厚型梗阻性心肌病(hypertrophic obstructive car-diomyopathy,HOCM)是原发性心肌病的一种特殊类型,约占肥厚型心肌病患者的25%[1]。临床治疗的目的是使流出道变宽,狭窄减轻,从而达到缓解流出道梗阻,减轻症状,降低猝死率。目前治疗的方法有     

Use of Hancock porcine xenografts in children and adolescents

Between January 1,1974 and December 31,1978,47 xenografts (8 aortic, 28 mitral, 4 tricuspid, 3 left atrioventricular valve in I-transposition of the great arteries and 3 aortic-mitral) were implanted in 44 patients, aged 10/12 to 20 5/12 years (median 12 2/12). All eight patients with aortic valve replacement survived and were followed up for 22.5 ± 10.4 months (mean ± standard error of the mean). At postoperative cardiac catheterization in three patients, the peak systolic ejection gradient ranged between 24 and 38 mm Hg and the valve area index between 0.71 and 1.15 cm²/m². Among 26 patients who underwent mitral valve replacement, 5 died operatively and 2 died 2 months postoperatively, leaving 19 long-term survivors who were followed up for 26.2 ± 15.6 months. In the 11 patients who underwent postoperative cardiac catheterization, the mean diastolic gradient was 6.1 ± 2.7 mm Hg and the mean valve index 1.79 ± 0.76 cm²/m². Severe subaortic obstruction, due to the prosthetic mitral valve, occurred in three of five patients less than 5 years old.Among four patients who underwent tricuspid valve replacement there were no operative deaths; complete heart block occurred in three. At postoperative catheterization in two patients, the mean diastolic gradient was 3 and 5 mm Hg, and the valve index 1.32 and 1.7 cm²/m², respectively. Three patients with I-transposition of the great arteries who underwent replacement of the systemic atrioventricular valve were followed up for 12 to 37 months. At postoperative catheterization the mean diastolic gradient was 0 to 4 mm Hg and the valve index ranged from 1.68 to 1.88 cm²/m². Both aortic and mitral valves were replaced in three children. One died at operation and one 6 months after operation. The survivor has complete heart block but is in New York Heart Association functional class I.Eight xenografts (6 mitral, 1 left atrioventricular valve in I-transposition of the great arteries and 1 aortic) failed, requiring replacement 22 to 68 months after implantation. All were calcified to varying degrees. Valve failure began presenting 22 months after implantation, and of 25 valves implanted for 20 months or longer, 8 have been replaced. These 8 patients were younger (10.3 ± 0.2 years) at initial valve replacement than the other 17 patients (15.0 ± 0.3 years) followed up for 20 months or longer (p <0.05). High levels of γ-carboxyglutamic acid (GLA), a calciumbinding amino acid, were found in all six calcified xenografts analyzed, whereas none was found in a fresh porcine aortic valve or in an unimplanted xenograft. GLA-containing protein, laid down after implantation, may play a role in xenograft calcification.     

冠心病合并中重度缺血性二尖瓣关闭不全的外科治疗

目的探讨冠心病合并中重度缺血性二尖瓣关闭不全的外科治疗原则。方法选择冠心病合并中重度缺血性二尖瓣关闭不全的手术患者61例,并对患者的临床资料进行回顾性分析。结果 45例行冠状动脉旁路移植术+二尖瓣成形术,16例行冠状动脉旁路移植术+二尖瓣置换术,其中2例患者行二尖瓣置换术,术后早期死于心力衰竭,余59例均治愈岀院。术后复查超声心动图检查显示,左心室舒张末内径从(52.8±11.3)mm降至(47.9±8.9)mm(P<0.01),LVEF从(46±11)%升至(52±12)%,差异有统计学意义(P<0.01)。结论对于冠心病合并中重度缺血性二尖瓣关闭不全的手术患者,同期处理二尖瓣后效果满意。     

Outcome of Patients Undergoing Transcatheter Implantation of Aortic Valve With Previous Mitral Valve Prosthesis (OPTIMAL) Study

BackgroundTranscatheter aortic valve replacement (TAVR) is the gold standard for severe valvular aortic stenosis in patients at high/prohibitive surgical risk. This procedure has also been used in patients with previous mitral valve (MV) prostheses, with contrasting outcomes reported. The aim of this study is to describe procedural and early outcomes of patients with previous MV prostheses undergoing TAVR.MethodsThis is a retrospective registry of 154 patients with previous MV prostheses who underwent TAVR across high-volume medical centres at a mean of 11.7 ± 8.4 years after mitral surgery.ResultsMean mitroaortic distance at computed tomography was 9.7 ± 4.8 mm. Procedural success was achieved in 150 (97.4%) patients, with reduction of aortic gradients (42.6 ± 14.2 to 10.0 ± 7.0 mm Hg; P < 0.001). Device success was achieved in 133 (86.3%) patients. MV prosthesis interference by the TAVR device was observed in 2 patients; in both, the mitroaortic distance was <5 mm, with 1 complicated by TAVR prosthesis embolization. Periprocedural complications included 4 (2.6%) cerebrovascular accidents, 10 (6.6%) major vascular complications, 22 (14.4%) severe bleedings, 1 (0.7%) myocardial infarction, and 5 (3.2%) in-hospital deaths (all cases cardiovascular or procedure related). At a median follow-up of 13.5 (interquartile range 1.0 to 36.0) months, 26 (16.9%) deaths occurred; 15 (9.7%) were cardiac related. Late fatal mitral prosthesis thromboses occurred in 2 patients. We recorded a case of fatal hemorrhagic stroke; hospital readmission was observed in 25 (16.2%) patients due to worsening heart failure.ConclusionsTAVR in patients with previous mitral prostheses appears to be safe and feasible, with good hemodynamic results at 30-day and at longer-term follow-up.     

风湿性二尖瓣病变行二尖瓣成形术的效果分析

目的 探讨风湿性二尖瓣病变行二尖瓣成形术的临床效果。 方法 选取2016年1月至2020年1月在郑州大学第一附属医院心外科因风湿性二尖瓣病变治疗的133例患者为研究对象。其中46例患者行二尖瓣成形术（观察组）,87例患者行二尖瓣置换术（对照组）。观察组中男性10例,女性36例,平均年龄（53.80±8.87）岁;对照组中男性25例,女性62例,平均年龄（56.54±9.88）岁。收集两组患者的基线资料、术前超声结果、围手术期资料、随访资料（术后6个月）,分析二尖瓣成形术的临床效果。 结果 观察组的主动脉阻断时间、体外循环时间、住院时间与对照组相比,差异无统计学意义（P > 0.05）。观察组术后呼吸机辅助时间较对照组短[（9.4±1.6）h比（12.9±1.5）h],差异有统计学意义（P < 0.05）。观察组与对照组术后 6个月左房内径[（41.00±8.00）mm比（46.75±10.13）mm]、左室舒张末期内径[（45.49±5.90）mm比（47.87±5.66）mm]差异有统计学意义,且观察组小于对照组（P < 0.05）。 结论 二尖瓣成形术治疗风湿性二尖瓣病变的早期临床效果满意,有利于心脏重构,值得临床推广应用。